Joseph A. Libnoch

824 total citations
34 papers, 643 citations indexed

About

Joseph A. Libnoch is a scholar working on Oncology, Epidemiology and Genetics. According to data from OpenAlex, Joseph A. Libnoch has authored 34 papers receiving a total of 643 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 12 papers in Epidemiology and 9 papers in Genetics. Recurrent topics in Joseph A. Libnoch's work include Lung Cancer Research Studies (12 papers), Neuroendocrine Tumor Research Advances (10 papers) and Brain Metastases and Treatment (6 papers). Joseph A. Libnoch is often cited by papers focused on Lung Cancer Research Studies (12 papers), Neuroendocrine Tumor Research Advances (10 papers) and Brain Metastases and Treatment (6 papers). Joseph A. Libnoch collaborates with scholars based in United States. Joseph A. Libnoch's co-authors include Roger W. Byhardt, James D. Cox, Tom Anderson, Richard M. Hansen, Paul Y. Holoye, Paul S. Ritch, Michaël Baumann, Arthur J. Hartz, Robert H. Keller and Vincent Yakulis and has published in prestigious journals such as Biochemistry, Cancer and The American Journal of Medicine.

In The Last Decade

Joseph A. Libnoch

33 papers receiving 590 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Joseph A. Libnoch United States 18 269 175 152 139 133 34 643
William B. Mill United States 14 349 1.3× 159 0.9× 91 0.6× 158 1.1× 131 1.0× 22 776
Laurent H. Schwartz France 13 321 1.2× 265 1.5× 63 0.4× 172 1.2× 204 1.5× 16 896
J.M. Cosset France 15 241 0.9× 262 1.5× 45 0.3× 121 0.9× 76 0.6× 43 814
Eligio Grigoletto Italy 14 375 1.4× 221 1.3× 49 0.3× 119 0.9× 82 0.6× 54 745
W. E. C. Allt Canada 9 194 0.7× 161 0.9× 90 0.6× 111 0.8× 30 0.2× 11 675
Claudio Dazzi Italy 17 556 2.1× 494 2.8× 179 1.2× 154 1.1× 45 0.3× 57 982
M. Luboinski France 9 392 1.5× 232 1.3× 187 1.2× 224 1.6× 115 0.9× 13 857
Jackson Cundiff United States 10 258 1.0× 327 1.9× 74 0.5× 102 0.7× 35 0.3× 17 871
G. Haensgen Germany 10 130 0.5× 74 0.4× 73 0.5× 110 0.8× 42 0.3× 15 502
Florian Würschmidt Germany 19 330 1.2× 500 2.9× 51 0.3× 129 0.9× 61 0.5× 49 1.0k

Countries citing papers authored by Joseph A. Libnoch

Since Specialization
Citations

This map shows the geographic impact of Joseph A. Libnoch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph A. Libnoch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph A. Libnoch more than expected).

Fields of papers citing papers by Joseph A. Libnoch

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joseph A. Libnoch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph A. Libnoch. The network helps show where Joseph A. Libnoch may publish in the future.

Co-authorship network of co-authors of Joseph A. Libnoch

This figure shows the co-authorship network connecting the top 25 collaborators of Joseph A. Libnoch. A scholar is included among the top collaborators of Joseph A. Libnoch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joseph A. Libnoch. Joseph A. Libnoch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hansen, Richard M., Paul S. Ritch, Joseph A. Libnoch, & Tom Anderson. (1991). Continuous 5-Fluorouracil Infusion and Alpha Interferon in Advanced Cancers: A Report of Initial Treatment Results. The American Journal of the Medical Sciences. 301(4). 246–249. 7 indexed citations
2.
Hansen, Richard M., Timothy J. Moynihan, Edward J. Quebbeman, et al.. (1991). Continuous systemic 5-fluorouracil infusion in refractory prostatic cancer. Urology. 37(4). 358–361. 24 indexed citations
3.
Chitambar, Christopher R., et al.. (1991). Evaluation of continuous infusion low‐dose 5‐azacytidine in the treatment of myelodysplastic syndromes. American Journal of Hematology. 37(2). 100–104. 40 indexed citations
4.
Hansen, Richard M., et al.. (1990). 5-Fluorouracil Infusion and Low-Dose Weekly Cisplatin. American Journal of Clinical Oncology. 13(6). 485–488. 4 indexed citations
5.
Studemeister, Alex, Michael J. Ptacin, Charles H. Cunningham, & Joseph A. Libnoch. (1988). Unexplained Hypotension in Hodgkin’s Disease. Cardiology. 75(2). 154–156. 2 indexed citations
6.
Ash, Robert C., et al.. (1987). Clinical Cytometry and Immunophenotyping. Pathology and Immunopathology Research. 6(1). 64–76. 8 indexed citations
7.
Toohill, Robert J., James A. Duncavage, J. Frank Wilson, et al.. (1987). The effects of delay in standard treatment due to induction chemotherapy in two randomized prospective studies. The Laryngoscope. 97(4). 407–412. 46 indexed citations
8.
Byhardt, Roger W., Arthur J. Hartz, Joseph A. Libnoch, Richard M. Hansen, & James D. Cox. (1986). Prognostic influence of TNM staging and LDH levels in small cell carcinoma of the lung (SCCL). International Journal of Radiation Oncology*Biology*Physics. 12(5). 771–777. 29 indexed citations
9.
Baumann, Michaël, et al.. (1986). Immunoregulatory abnormalities in myelodysplastic disorders. American Journal of Hematology. 22(1). 17–26. 33 indexed citations
10.
Baumann, Michaël, et al.. (1986). Myeloid cell surface phenotype in myelodysplasia: Evidence for abnormal persistence of an early myeloid differentiation antigen. American Journal of Hematology. 22(3). 251–257. 15 indexed citations
11.
Komaki, Ritsuko, James D. Cox, Roger W. Byhardt, et al.. (1985). 27. What is the Lowest Effective Biologic Dose for Prophylactic Cranial Irradiation?. American Journal of Clinical Oncology. 8(1). 20–20. 4 indexed citations
12.
Baumann, Michaël, et al.. (1985). Prolonged survival in Richter syndrome with subsequent reemergence of CLL: A case report including serial cell‐surface phenotypic analysis. American Journal of Hematology. 20(1). 67–72. 4 indexed citations
13.
Holoye, Paul Y., Joseph A. Libnoch, Tom Anderson, et al.. (1985). Combined methotrexate and high-dose vincristine chemotherapy with radiation therapy for small cell bronchogenic carcinoma. Cancer. 55(7). 1436–1445. 8 indexed citations
14.
Komaki, Ritsuko, Roger W. Byhardt, Tom Anderson, et al.. (1985). What is the lowest effective biologic dose for prophylactic cranial irradiation?. American Journal of Clinical Oncology. 8(6). 523–527. 29 indexed citations
15.
Franson, Timothy R., et al.. (1984). Late-onset, warfarin-caused necrosis occurring in a patient with infectious mononucleosis.. PubMed. 120(7). 927–31. 26 indexed citations
16.
Libnoch, Joseph A., et al.. (1983). Fc gamma bearing T cells in non-Hodgkin lymphoma.. PubMed. 1(1). 27–32. 1 indexed citations
17.
Holoye, Paul Y., Joseph A. Libnoch, Roger W. Byhardt, & James D. Cox. (1982). Integration of chemotherapy and radiation therapy for small cell carcinoma of the lung. International Journal of Radiation Oncology*Biology*Physics. 8(9). 1593–1596. 6 indexed citations
18.
Cox, James D., Paul Y. Holoye, Roger W. Byhardt, et al.. (1982). The role of thoracic and cranial irradiation for small cell carcinoma of the lung. International Journal of Radiation Oncology*Biology*Physics. 8(2). 191–196. 19 indexed citations
19.
Byhardt, Roger W., James D. Cox, Joseph A. Libnoch, & Paul Y. Holoye. (1979). Local control of intrathoracic and CNS sites with chemotherapy and prophylactic CNS irradiation in small cell carcinoma of the lung. 6. 1 indexed citations
20.
Libnoch, Joseph A., et al.. (1977). Acute myelofibrosis and malignant hypercalcemia. The American Journal of Medicine. 62(3). 432–438. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by William B. Mill Breakdown of academic impact, for papers by Laurent H. Schwartz Breakdown of academic impact, for papers by J.M. Cosset Breakdown of academic impact, for papers by Eligio Grigoletto Breakdown of academic impact, for papers by W. E. C. Allt Breakdown of academic impact, for papers by Claudio Dazzi Breakdown of academic impact, for papers by M. Luboinski Breakdown of academic impact, for papers by Jackson Cundiff Breakdown of academic impact, for papers by G. Haensgen Breakdown of academic impact, for papers by Florian Würschmidt
Rankless by CCL
2026